FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Enrique Sanz‐García; Samantha Brown; Jessica A. Lavery; Jessica Weiss; Hannah E. Fuchs; Ashley Newcomb; Asha Postle; Jeremy L. Warner; Michele L. Lenoue-Newton; Shawn M. Sweeney; Shirin Pillai; Celeste Yu; Chelsea Nichols; Brooke Mastrogiacomo; Ritika Kundra; Nikolaus Schultz; Kenneth L. Kehl; Gregory J. Riely; Deborah Schrag; Anand Govindarajan; Katherine S. Panageas; Philippe L. Bédard

doi:10.1158/2767-9764.25248652.v1

Abstract

PFS from initiation of first-line cancer-directed regimen (A, PM vs. non-PM; B, PM only vs. PM and other sites vs. non-PM; C, stage IV: PM only vs. PM and other sites vs. non-PM; D, stage I–III with later development of distant metastasis: PM vs. non-PM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sanz‐García et al. (2024) studied this question.

synapsesocial.com/papers/68e7880eb6db6435876fa653 https://doi.org/10.1158/2767-9764.25248652.v1

View Full Paper

Ask AI

Bookmark

Share

FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Abstract

Discussion

Cite This Study

FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Abstract

Discussion

Cite This Study

Keep reading

Keep reading